Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025.

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He noted, "We met or ...

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

He will then hand off the role to Dr. Johanna Bendell, who will join the Pfizer team in 2025. Dansey has years of experience leading clinical development efforts of notable cancer medications like ...

Guardant Health, Inc. GH on Thursday announced a strategic collaboration with Pfizer, Inc. PFE to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant ...

Pfizer Inc will drop efforts to develop medicines for heart disease, obesity and bone health as part of its plan to focus research on cancer and five other therapeutic areas, a company memo showed.

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025.

Pfizer reported Q4 2024 revenue of $17.8 billion, with $13.7 billion from non-COVID products, reflecting 11% operational year-over-year growth. Key growth drivers included the Vyndaqel family ...